CordenPharma completes early development suite at Plankstadt facility

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Golden_Brown)
(Image: iStock/Golden_Brown)
CordenPharma has completed development of an early development suite for highly potent, oral solid dosage products at its Plankstadt, Germany location.

According to the contract manufacturing organization (CMO), the new facility enables the production of small batches from 100g to approximately 1,000g. The facility is able to provide compounds with various potencies and containment degrees.

"The setup in the new facility of CordenPharma Plankstadt is very flexible – it allows for operations to take place at three different levels of containment​," said Jason Bertola, director, global highly potent and oncology platform, CordenPharma International.

"Basically, it progresses from an open system for non-highly potent ​compounds, to a semi-closed system (sliding glass pane) to a fully enclosed system for OEL below 1mg/m3. The containment systems can be connected by Rapid Transfer Port (RTP) to allow the transfer in and out of the individual barriers safely​," he told us. 

As Bertola explained, the production of small technical batches was a gap in CordenPharma's service offering and the new facility addresses this gap. "This area is non-GMP and designed for development work​," he added.

The addition follows a series of investments made during the past year, including expanded capacity and capabilities at its Boulder, Colorado facility in the US.

The company has also recently implemented​ a program to address corporate and quality systems, organization structure and infrastructure, and includes a process to involve customers in improving transparency. 

Related topics: Contract Manufacturing

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers